2022 | First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study | JOURNAL OF CLINICAL ONCOLOGY |
2022 | First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY |
2021 | First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
| FUTURE ONCOLOGY |
2009 | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009 | LANCET ONCOLOGY |
2020 | First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
| CANCERS |
2024 | First-year cumulative myeloperoxidase-ANCA titres are associated with all-cause mortality in patients with microscopic polyangiitis
| CLINICAL AND EXPERIMENTAL RHEUMATOLOGY |
2017 | Five factor score of more than 1 is associated with relapse during the first 2 year-follow up in patients with eosinophilic granulomatosis with polyangiitis | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES |
2021 | Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC | JOURNAL OF THORACIC ONCOLOGY |
2019 | Five-Year Change in the Renal Function After Catheter Ablation of Atrial Fibrillation
| JOURNAL OF THE AMERICAN HEART ASSOCIATION |
2016 | Five-year decreased incidence of surgical site infections following gastrectomy and prosthetic joint replacement surgery through active surveillance by the Korean Nosocomial Infection Surveillance System. | JOURNAL OF HOSPITAL INFECTION |
2011 | Five-year outcomes of sirolimus-eluting versus paclitaxel-eluting stents: a propensity matched study: clinical evidence of late catch-up? | INTERNATIONAL JOURNAL OF CARDIOLOGY |
2023 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
| JOURNAL OF CLINICAL ONCOLOGY |
2022 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
| JOURNAL OF CLINICAL ONCOLOGY |
2017 | FK506, an Immunosuppressive Drug, Induces Autophagy by Binding to the V-ATPase Catalytic Subunit A in Neuronal Cells | JOURNAL OF PROTEOME RESEARCH |
2012 | FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study | PSYCHONEUROENDOCRINOLOGY |
2016 | Flagellin suppresses experimental asthma by generating regulatory dendritic cells and T cells | JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY |
2001 | Flail aortic valve and acute aortic regurgitation due to spontaneous localized intimal tear of ascending aorta. | ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES |
2013 | Flecainide-Associated Bradycardia-Dependent Torsade de Pointes: Another Potential Mechanism of Proarrhythmia | PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY |
1994 | Flexible Coil (Gianturco-Roubin) Coronary Stent의 초기 임상 경험
| KOREAN CIRCULATION JOURNAL(순환기) |
1995 | Flexible Coil(Gianturco-Roubin) coronary Stent 삽입후의 혈관 병리 소견
| KOREAN CIRCULATION JOURNAL(순환기) |